Epaminurad is an investigational new drug being developed by JW Pharmaceutical for the treatment of gout and hyperuricemia. It is a urate-lowering agent that selectively inhibits the human uric acid transporter 1 (hURAT1), promoting urate excretion.[1][2] As of 2024, epaminurad is undergoing Phase 3 clinical trials to evaluate its efficacy and safety compared to febuxostat in gout patients across multiple Asian countries.[3][1]

References

  1. ^ a b "JW Pharmaceutical's Epaminurad Shows Promise for Gout Treatment". Business Korea. 16 January 2024. Retrieved 2024-11-23.
  2. ^ Hou X, Wang Y, Yang Y, Xiao Z (November 2023). "Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors". Molecules. 28 (21). Basel, Switzerland: 7415. doi:10.3390/molecules28217415. PMC 10648204. PMID 37959834.
  3. ^ Khaja H (9 February 2024). "Emerging Drug Treatments for Gout". Rheumatology Advisor. Retrieved 2024-11-23.
Allikas: http://en.wikipedia.org/wiki/Epaminurad
No tags for this post.